Stockscreener 앱 받기
4.55
4.12%
0.18
시간 외 거래:
4.57
0.02
+0.44%
전일 마감가:
$4.37
열려 있는:
$4.69
하루 거래량:
82,377
Relative Volume:
0.99
시가총액:
$108.25M
수익:
-
순이익/손실:
$-44.10M
주가수익비율:
-2.1291
EPS:
-2.1371
순현금흐름:
$-49.09M
1주 성능:
+9.37%
1개월 성능:
-7.14%
6개월 성능:
-56.33%
1년 성능:
+77.73%
1일 변동 폭
$4.46
$4.7491
1주일 범위
$4.10
$4.7491
52주 변동 폭
$2.14
$11.88
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
명칭
Kalaris Therapeutics Inc
전화
650-249-2727
주소
400 CONNELL DRIVE, BERKELEY HEIGHTS
Compare KLRS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
4.55 | 101.59M | 0 | -44.10M | -49.09M | -2.1371 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-16 | 개시 | Morgan Stanley | Overweight |
| 2025-12-23 | 개시 | Chardan Capital Markets | Buy |
| 2025-11-03 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-07-23 | 재개 | Piper Sandler | Neutral |
| 2025-05-07 | 개시 | Leerink Partners | Outperform |
| 2025-04-08 | 개시 | William Blair | Outperform |
모두보기
Kalaris Therapeutics Inc 주식(KLRS)의 최신 뉴스
KLRS Initiates Coverage On by TD Cowen -- Rating Set to Buy - GuruFocus
Kalaris Therapeutics initiated with a Buy at TD Cowen - TipRanks
TD Cowen initiates Kalaris stock coverage with buy rating By Investing.com - Investing.com Canada
TD Cowen initiates Kalaris stock coverage with buy rating - Investing.com
KLRS SEC FilingsKalaris Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Kalaris to Present at Clinical Trials at the Summit 2026 - Investing News Network
First-in-human TH103 eye trial data to be presented at Las Vegas summit - Stock Titan
KLRS Q1 2026 Earnings: Narrower Loss Beats Estimates Amid Clinical Development ProgressEPS Revision Trend - newsline.com
KLRS Q1 2026 Earnings: EPS Beat Amid Pre-Revenue Development StageAnalyst Earnings Estimate - newsline.com
Why Is Kalaris Therapeutics Inc (KLRS) Stock Down Today? - Meyka
Kalaris Therapeutics Shareholders Back Board, Pay and Auditor - TipRanks
Kalaris Therapeutics (KLRS) director granted 9,000 stock options - Stock Titan
Kalaris Therapeutics (KLRS) director receives stock options for 9,000 shares - Stock Titan
Kalaris Therapeutics (KLRS) director receives 9,000-stock option grant - Stock Titan
[Form 4] Kalaris Therapeutics, Inc. Insider Trading Activity - Stock Titan
Kalaris Therapeutics (KLRS) director awarded 9,000 stock options - Stock Titan
Kalaris Therapeutics (KLRS) director receives stock options on 9,000 shares - Stock Titan
Kalaris Therapeutics (KLRS) holders elect board, choose annual say-on-pay - Stock Titan
Kaskela Law LLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. Shareholders and Encourages Investors With Losses to Contact The FirmKLRS - ACCESS Newswire
Kalaris Therapeutics (KLRS) Slides 6.33% as Selling Pressure Mounts; Key Support in FocusMFI Overbought - newsline.com
Wedbush Maintains Kalaris Therapeutics(KLRS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Number of shareholders of Kalaris Therapeutics, Inc. – NASDAQ:KLRS - TradingView
Kalaris Therapeutics (KLRS) Surges 7.72% as Shares Approach Key ResistanceVolume Breakout Ideas - newsline.com
Kalaris Therapeutics director Akkaraju’s fund buys $1.18m stock By Investing.com - Investing.com Nigeria
Kalaris Therapeutics director Akkaraju’s fund buys $1.18m stock - Investing.com
Samsara entities boost control in Kalaris (KLRS) with 54.2% stake and intra-fund share deal - Stock Titan
Kalaris Therapeutics (KLRS) affiliate adds 244,300 KLRS shares - Stock Titan
Kalaris Therapeutics Inc. (KLRS) Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Disciplined SpendingRevenue Growth Outlook - newsline.com
Kalaris Therapeutics (KLRS) Rallies +4.36% as Bulls Target $5.16 2026-05-20Covered Call ETF - Newser
Kalaris Therapeutics (KLRS) Falls -2.87% — Watching $4.82 Support 2026-05-15Open Signal Network - Newser
Kalaris Therapeutics (KLRS) Stock: Up +8.90%, Key Resistance at $5.52 2026-05-14MACD Signals - newser.com
Wedbush Initiates Kalaris Therapeutics at Outperform With $17 Price Target - Moomoo
Citizens cuts Kalaris stock price target on manufacturing progress By Investing.com - Investing.com South Africa
Citizens cuts Kalaris stock price target on manufacturing progress - Investing.com
Morgan Stanley Maintains Kalaris Therapeutics(KLRS.US) With Buy Rating, Maintains Target Price $14 - Moomoo
[10-Q] Kalaris Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Kalaris Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Raymond James reiterates Strong Buy on Kalaris stock amid trial progress - Investing.com Nigeria
Kalaris Therapeutics Reports Q1 2026 Financial Results and Advances TH103 Clinical Trials for Retinal Diseases - Minichart
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates - Investing News Network
Kalaris Therapeutics posts smaller-than-expected Q1 net loss - TradingView
Kalaris Therapeutics (KLRS) posts Q1 2026 loss with $104.9M cash to fund trials into 2027 - Stock Titan
Eye drug TH103 nears dosing as Kalaris funds trials into 2027 - Stock Titan
Press Release: Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates - Moomoo
William Blair Maintains Kalaris Therapeutics(KLRS.US) With Buy Rating - Moomoo
TradingKey - TradingKey
KLRS: Kalaris Therapeutics Inc.Interactive Chart - Zacks Investment Research
KLRS Kalaris Therapeutics Q4 loss narrows more than expected, lifting shares 1.78% on positive sentiment.Financial Data - Newser
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Short Interest Update - MarketBeat
Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know - MSN
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Kalaris Therapeutics Inc (KLRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kalaris Therapeutics Inc 주식 (KLRS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hagen Brett R | Chief Accounting Officer |
Mar 20 '26 |
Sale |
6.72 |
1,915 |
12,869 |
0 |
2.60%
0.94%
자본화:
|
볼륨(24시간):